Philips’ computed tomography (CT) solutions suite has just been granted 510(k) clearance from the US Food and Drug Administration for low-dose lung cancer screening (LCS). The approval means any hospital or healthcare facility with one of the company’s (CT) models will now be eligible to become a lung cancer screening center, according to Royal Philips.
The suite, with its 27 CT and PET/CT models, plus integrated software and services, together provide what Philips claims is the most comprehensive lung cancer screening solution in the field.
Lung cancer is the leading cause of cancer death among both men and women in the US, and the source of one in four cancer deaths. Lung cancer screenings are recommended by the Center for Medicare & Medicaid Services (CMS) to help earlier diagnosis of the disease in high-risk populations at a stage where treatment can be more successful.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive